Reduced Haloperidol/Haloperidol ratio and clinical outcome in schizophrenia: Preliminary evidences

Carlo Altamura, Massimo Mauri, Roberto Cavallaro, Fulgenzio Colacurcio, Alfredo Gorni, Silvio Bareggi

Research output: Contribution to journalArticlepeer-review


1. 1. The possible influence of haloparidol and its metabolite plasma levels on clinical outcome in schizophrenic patients was evaluated. 2. 2. 18 schizophrenic inpatients diagnosed according to DSM III, were treated with conventional haioperidol p.o. for four weeks. 3. 3. Plasma levels of haloperidol and its reduced metabolite were measured by massspectrometry assay. Clinical outcome was evaluated by BPRS, 4. 4. Cluster analysis only considering BPRS improvement and reduced haloperidol/haloperidol ratio was'able to discriminate two groups of patients: one of non responders and the other of responders. The former group presented higher ratios than the latter. 5. 5. Reduced haloperidol/haloperidol ratio could be considered as a good marker for prediction of the clinical outcome.

Original languageEnglish
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Issue number5
Publication statusPublished - 1988


  • clinical outcome
  • reduced haloperidol
  • schizophrenia

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology


Dive into the research topics of 'Reduced Haloperidol/Haloperidol ratio and clinical outcome in schizophrenia: Preliminary evidences'. Together they form a unique fingerprint.

Cite this